1. Background {#sec68731}
=============

Laparoscopic cholecystectomy is usually preferred for symptomatic cholelithiasis. Despite many benefits of laparoscopic surgery, many patients complain of pain postoperatively. This may lead to prolonged hospital stay and increased morbidity, which is particularly important in centers performing this operation as a day case procedure ([@A17206R1]). In addition to opioids, several methods have been used for pain relief after laparoscopic cholecystectomy including nonopioid analgesics ([@A17206R2]), intravenous Paracetamol ([@A17206R3]), perioperative parecoxib ([@A17206R4]), administration of intraperitoneal local anesthetics alone ([@A17206R5]-[@A17206R7]) or in combination with nonopioid analgesics ([@A17206R8], [@A17206R9]). This might reduce adverse effects of opioids. Furthermore, steroids have also been used successfully for postoperative pain relief in different kinds of surgery ([@A17206R10]-[@A17206R12]). Sarvestani et al. showed that intraperitoneal hydrocortisone can reduce pain after laparoscopic cholecystectomy without significant adverse effects ([@A17206R13]).

2. Objectives {#sec68732}
=============

The purpose of this study was to compare administration of intraperitoneal glucocorticoids with bupivacaine for pain relief after laparoscopic cholecystectomy. The primary outcome was to compare pain scores between the two groups. The secondary outcomes included postoperative analgesic requirements, frequency of nausea and vomiting, duration of hospital stay, time of return of bowel function, time of unassisted ambulation, and time of oral intake.

3. Patients and Methods {#sec68733}
=======================

After approval of the local ethics committee and informed consent, 63 patients of ASA physical status I-II scheduled for elective laparoscopic cholecystectomy were included in the study. Exclusion criteria were patients with chronic pain other than gallstone disease, use of opioids, tranquilizers, steroids, NSAIDs, and alcohol, patients with acute cholecystitis, allergy to corticosteroids, neuromuscular diseases and bleeding disorders.

After receiving 5 mL/kg crystalloids, preoxygenation with 100% O~2~ for 3 minutes, 2 μg/kg of fentanyl and 0.05 mg/kg of midazolam, anesthesia was induced with thiopental 5 mg/kg followed by 0.15 mg/kg of cisatracurium to facilitate endotracheal intubation. Anesthesia was maintained with 60% N~2~O in oxygen and propofol 4-6 mg/kg/h (to keep the cerebral state index at 40-60) and remifentanil 0.05-0.5 μg/kg/min (to maintain mean arterial blood pressure and pulse rates within 20% of the baseline). All patients received 1 μg/kg fentanyl five minutes before the end of operation for postoperative pain relief.

After receiving the standard anesthesia and before insufflations of CO~2~, the patients were allocated randomly (using random table) to receive either instillation of 100 mg bupivacaine in 250 mL of normal saline or 100 mg hydrocortisone in 250 mL normal saline into the peritoneum by a surgical scrub nurse blinded to the study design. Then, patients were positioned in Trendelenburg, anti-Trendelenburg, left and right lateral decubitus and finally supine positions (each for 2 minutes). Nasogastric tube was inserted for all patients after induction and was removed at the end of operation. All surgical procedures were performed by a single surgeon. During laparoscopy, intraabdominal pressure was maintained at 14 mmHg. Carbon dioxide was carefully evacuated at the end of operation by manual compression of the abdomen with open trocars. Ten milliliters of bupivacaine 0.25% was injected in laparoscopy entering sites. Patients were followed by a blinded investigator regarding postoperative abdominal and shoulder pain using VAS based on a 0-10 scale (with 0 indicating no pain and 10 as the most severe pain ever experienced), postoperative analgesic requirements, presence of nausea and vomiting, time of unassisted ambulation, time of oral intake and time of return of bowel function in recovery room and at 6, 12 and 24 hours after the operation. Time of return of bowel function was defined as the time from the end of anesthesia until the presence of bowel sound or first passage of flatus. We administered intramuscular meperidine 0.5 mg/kg and 1 mg/kg as rescue analgesic for VAS 4-7, and 8-10, respectively. Patients received standard monitoring including pulse rates, noninvasive blood pressure, electrocardiography, respiratory rate, temperature, pulse oximetry, and capnography.

Using SPSS software for Windows, version 15 (SPSS Inc., Chicago, IL, USA), arithmetic mean and standard deviation values for different variables were calculated and statistical analyses were performed for each group. We used independent Student T-test to compare continuous variables with normal distribution, and Chi-square and Mann-Whitney U test for non-continuous variables. P value less than 0.05 was considered significant.

4. Results {#sec68734}
==========

Sixty patients completed the study. Three were excluded since conversion to open cholecystectomy was necessary because of dense inflammatory adhesions. There were no statistically significant differences between the two groups regarding demographic characteristics and duration of operation ([Table 1](#tbl17498){ref-type="table"}). The patients were similar regarding factors likely to increase postoperative pain including bile spillage from punctured gallbladder, difficult dissection due to adhesions from previous surgery, bleeding, need to cholangiography, injury to bowels or other organs, and insertion of drain. Abdominal and shoulder pain scores were not significantly different between the two groups and the patients were almost pain free after 12 hours ([Tables 2](#tbl17499){ref-type="table"} and [3](#tbl17500){ref-type="table"}). The patients were similar regarding analgesic requirements in recovery room and 6, 12 and 24 hours after the operation ([Table 4](#tbl17501){ref-type="table"}). The patients were similar regarding the frequency of nausea and vomiting, duration of hospital stay, time of return of bowel function, time of unassisted ambulation, and time of oral intake ([Table 5](#tbl17502){ref-type="table"}).

###### Patients Data and Operation Characteristics ^[a](#fn14439){ref-type="table-fn"}^

  Data                                Bupivacaine Group   Hydrocortisone Group   P Value ^[b](#fn14440){ref-type="table-fn"}^
  ----------------------------------- ------------------- ---------------------- ----------------------------------------------
  **Age, y**                          44.16 ± 8.39        44.6 ± 3.32            NS
  **Gender, female:** **male**        18:12               19:11                  NS
  **Weight, kg**                      70.03 ± 9.60        72.2 ± 7.94            NS
  **Height, cm**                      162.2 ± 5.99        162.0 ± 5.45           NS
  **Duration of**operation**, min**   94.16 ± 11.22       93.86 ± 10.38          NS

^a^ Data are presented as mean ± SD or No.

^b^ NS: not significant.

###### Visual Analogue Abdominal Pain Scores in the Two Groups ^[a](#fn14441){ref-type="table-fn"}^

  Group, time                    Bupivacaine Group   Hydrocortisone Group   P Value ^[b](#fn14442){ref-type="table-fn"}^
  ------------------------------ ------------------- ---------------------- ----------------------------------------------
  **In the recovery room, mg**   4.33 ± 0.84         4.23 ± 0.77            NS
  **At 6 hours, mg**             3.33 ± 0.84         3.13 ± 0.73            NS
  **At 12 hours, mg**            2.53 ± 0.57         2.26 ± 0.58            NS
  **At 24 hours, mg**            1.53 ± 0.57         1.33 ± 0.47            NS

^a^ Data are presented as mean ± SD.

^b^ NS: not significant.

###### Visual Analogue Shoulder Pain Scores in the Two Groups ^[a](#fn14443){ref-type="table-fn"}^

  Group, time                    Bupivacaine Group   Hydrocortisone Group   P Value ^[b](#fn14444){ref-type="table-fn"}^
  ------------------------------ ------------------- ---------------------- ----------------------------------------------
  **In the recovery room, mg**   1.93 ± 0.784        1.93 ± 0.784           NS
  **At 6 hours, mg**             1.53 ± 0.507        1.6 ± 0.498            NS
  **At 12 hours, mg**            1.66 ± 0.461        1.2 ± 0.406            NS
  **At 24 hours, mg**            0.53 ± 0.507        0.63 ± 0.49            NS

^a^ Data are presented as mean ± SD.

^b^ NS: not significant.

###### Postoperative Meperidine Requirements in the Two Groups ^[a](#fn14445){ref-type="table-fn"}^

  Group, time                    Bupivacaine Group   Hydrocortisone Group   P Value ^[b](#fn14446){ref-type="table-fn"}^
  ------------------------------ ------------------- ---------------------- ----------------------------------------------
  **In the recovery room, mg**   40.00 ± 20.34       40.00 ± 20.34          NS
  **At 6 hours, mg**             25.00 ± 25.42       21.66 ± 25.2           NS
  **At 12 hours, mg**            15.00 ± 23.3        00                     NS
  **At 24 hours, mg**            00                  00                     NS

^a^ Data are presented as mean ± SD.

^b^ NS: not significant.

###### Recovery Variables Between the Two Groups ^[a](#fn14447){ref-type="table-fn"}^

  Group, time                            Bupivacaine Group   Hydrocortisone Group   P Value ^[b](#fn14448){ref-type="table-fn"}^
  -------------------------------------- ------------------- ---------------------- ----------------------------------------------
  **Time of oral intake, h**             12.7 ± 1.44         12.3 ± 1.49            NS
  **Time of unassisted ambulation, h**   14.66 ± 1.47        14\. 6 ± 1.49          NS
  **Time of bowel function, h**          18.96 ± 1.54        18.6 ± 1.49            NS
  **Time of hospital stay, h**           27.86 ± 1.87        27.5 ± 1.88            NS

^a^ Data are presented as mean ± SD.

^b^ NS: not significant.

5. Discussion {#sec68735}
=============

We demonstrated that intraperitoneal administration of hydrocortisone could decrease pain and analgesic requirements similar to intraperitoneal bupivacaine after laparoscopic cholecystectomy without significant adverse effects. Provision of adequate postoperative pain relief is of considerable importance following day case laparoscopic cholecystectomy ([@A17206R1]). Pain after laparoscopic cholecystectomy is affected by several factors including patient demographics, nature of underlying disease, surgical factors, volume of residual gas, and type of gas used for pneumoperitoneum, and the pressure created by the pneumoperitoneum ([@A17206R13]-[@A17206R18]). A number of techniques were described to reduce post-laparoscopy pain including preincisional infiltration and intraperitoneal instillation of levobupivacaine 0.25% ([@A17206R19]), intraperitoneal ropivacaine and a gas drain ([@A17206R20]), intraperitoneal levobupivacaine with epinephrine ([@A17206R21]), intraperitoneal application of bupivacaine plus morphine ([@A17206R22]), preincisional injection of bupivacaine ([@A17206R23]), preemptive intraperitoneal injection of ropivacaine ([@A17206R24]) and intraperitoneal lidocaine combined with intravenous or intraperitoneal tenoxicam ([@A17206R25]). It is suggested that post-laparoscopic cholecystectomy pain is multifactorial and methods for short-term analgesia cannot improve postoperative functions or shorten hospitalization ([@A17206R26]). It has been shown that glucocorticoids can play a crucial role in the regulation of inflammatory responses through both genomic and nongenomic mechanisms and therefore may reduce pain ([@A17206R27]). Among corticosteroids, dexamethasone has been used widely to reduce postoperative pain ([@A17206R21], [@A17206R28], [@A17206R29]). The mechanism of analgesic effect of steroids is not well known.

Proposed analgesic mechanisms of steroids include suppression of tissue levels of bradikinin and release of neuropeptides from nerve endings, reduction in prostaglandin production inhibiting the synthesis of cyclooxygenase isoform-2 in peripheral tissues and central nervous system; inhibition of other mediators of inflammatory hyperalgesia, for example, tumor necrosis factor-a, interleukin-17 b, and interleukin-6. Except one study by Sarvestani et al. ([@A17206R13]) on laparoscopic cholecystectomy, the effect of intraperitoneal corticosteroids on pain after elective laparoscopic procedures has not been investigated. We assumed that early postoperative pain was mainly caused by irritation of the peritoneum, and application of corticosteroids may attenuate this. We used intraperitoneal hydrocortisone successfully to reduce pain following laparoscopic cholecystectomy like intraperitoneal bupivacaine.

In conclusion, our study showed that intraperitoneal injection of hydrocortisone before gas insufflation can reduce postoperative pain similar to intraperitoneal bupivacaine with no significant postoperative adverse effects in laparoscopic cholecystectomy.
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